.avif)
.avif)
Beam Therapeutics Email Format
Biotechnology Research
・
501-1,000 employees
・
Cambridge, MA, USA
Beam Therapeutics is a biotechnology company pioneering CRISPR base editing technology to develop precision genetic medicines for patients with serious diseases.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@beamtx.com
Company Overview
Industry
Biotechnology Research
Founded
2017
Headquarters
Cambridge, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
John Evans (Chief Executive Officer), Sravan K. Emany (Chief Financial Officer), Manmohan Singh, Ph.D. (Chief Technology Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Beam Therapeutics?
Beam Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@beamtx.com.
What is Beam Therapeutics' lead program in its genetic disease pipeline?
BEAM-302 is Beam Therapeutics' lead genetic disease program, an in vivo base editing therapy targeting alpha-1 antitrypsin deficiency delivered via lipid nanoparticles. The program is in an ongoing Phase 1/2 trial and is pursuing an accelerated approval pathway with the FDA.
Which therapeutic areas does Beam Therapeutics focus on?
Beam Therapeutics focuses on two main therapeutic areas: liver-targeted genetic diseases, including alpha-1 antitrypsin deficiency, glycogen storage disease type Ia, and phenylketonuria, and hematology, with programs targeting sickle cell disease.
How can I find and verify a Beam Therapeutics employee contact for outreach?
Since Beam Therapeutics uses the firstinitiallast format at beamtx.com, you can construct likely addresses directly. Tools like Clay can help you verify specific contacts and enrich prospect lists with accurate Beam Therapeutics employee data before you reach out.
Who leads Beam Therapeutics as CEO in 2026?
John Evans serves as Chief Executive Officer of Beam Therapeutics in 2026, alongside Sravan K. Emany as Chief Financial Officer and Manmohan Singh, Ph.D. as Chief Technology Officer.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating